GlassScriptPhysician profile
Muhammad Majeed
NPI 1174825814
$5,490.04
in general payments reported to CMS, 2019-2025
20 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $324 · 2021: $523 · 2022: $1,960 · 2023: $474 · 2024: $763 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Travel and Lodging: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.80 |
| Travel and Lodging | $359.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,636.72 | 2021-2024 | Intellis Adaptivestim, Fusion |
| Boston Scientific Corporation | $1,062.28 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Stryker Corporation | $777.12 | 2022 | |
| Abbott Laboratories | $430.57 | 2019-2020 | |
| Abbvie INC. | $303.89 | 2021-2025 | |
| Mml US, INC. | $203.03 | 2023 | Reactiv8 |
| Medtronic USA, INC. | $162.72 | 2019-2020 | |
| Vertos Medical, INC. | $151.85 | 2022 | |
| Lundbeck LLC | $143.17 | 2024-2025 | Vyepti |
| Nevro Corp. | $131.30 | 2022 | |
| Collegium Pharmaceutical, INC. | $128.21 | 2021-2024 | Xtampza, Belbuca |
| Averitas Pharma INC. | $118.09 | 2024-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $66.94 | 2023 | Spravato |
| Amgen INC. | $37.60 | 2022 | |
| Bioventus LLC | $32.55 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $30.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $24.23 | 2025 | |
| Revance Therapeutics, INC. | $20.27 | 2025 | Daxxify |
| Relievant Medsystems, INC. | $14.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Majeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.